GlassScriptPhysician profile
Berton Taffet
NPI 1366430209
$1,735.35
in general payments reported to CMS, 2019-2025
14 companies · $534 in 2025
The $534 reported for 2025 was less than what a typical Adult Reconstructive Orthopaedic Surgery provider received nationally (typical 2025 total: $1,425).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $289 · 2020: $49.28 · 2021: $80.75 · 2022: $201 · 2023: $350 · 2024: $231 · 2025: $534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,115.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $816.98 | 2019-2025 | Euflexxa |
| Bioventus LLC | $187.07 | 2020-2025 | Durolane, Durolane, Exogen Ultrasound Bone Healing System |
| Zimmer Biomet Holdings, INC. | $149.70 | 2025 | Rosa |
| Depuy Synthes Sales INC. | $132.37 | 2019-2025 | Monovisc, Orthovisc |
| Stryker Corporation | $124.06 | 2023-2024 | Mako, Variax |
| Pacira Therapeutics, INC. | $79.35 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $46.99 | 2022-2023 | Seglentis |
| Pacira Pharmaceuticals Incorporated | $44.68 | 2023-2025 | Exparel, Iovera, Zilretta |
| Endo Pharmaceuticals INC. | $42.53 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $28.31 | 2019 | |
| Davol INC. | $27.32 | 2022 | |
| Kerecis Limited | $22.84 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Alexion Pharmaceuticals, INC. | $18.59 | 2025 | Strensiq |
| Fidia Pharma USA INC. | $14.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Berton Taffet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.